Q-omics provides the consensus-scored EEF1GP8 profile across patient tissues and cancer cell-line models. EEF1GP8 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, EEF1GP8 is differentially expressed in 6, with the highest sampling consensus in COAD. Additionally, EEF1GP8 RNA expression shows 5,491 significant pathway-activity associations, with the highest sampling consensus in UCEC. Together, these results highlight KIRC, COAD, and UCEC as cancer lineages where EEF1GP8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EEF1GP8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EEF1GP8 survival associations across molecular data types. EEF1GP8 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EEF1GP8 RNA expression–survival associations across cancer types. High EEF1GP8 expression shows unfavorable associations in CHOL, LIHC and CESC, but favorable associations in KIRC, THCA and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .006). Together, the overview and detailed table identify KIRC as the clearest survival context for EEF1GP8 RNA expression.
This table summarizes EEF1GP8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for EEF1GP8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EEF1GP8 shows lower tumor expression in KICH and higher tumor expression in COAD, HNSC, PRAD, STAD and LIHC. The COAD box plot shows higher EEF1GP8 RNA expression in tumor versus normal tissue (log2 FC = +0.195, t-test p < 0.001).
This table shows molecular features associated with EEF1GP8 in patient tissues and cancer cell lines. In patient samples, EEF1GP8 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set.
